Home › Research › Vascular contributions
Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs
Burdett P, Lip GYH.. European heart journal. Quality of care & clinical outcomes, 2022-03-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Atrial fibrillation already accounts for a significant amount of National Health Service (NHS) funding, and over the coming years is highly likely to impose a growing cost on NHS budgets and the wider UK healthcare system. Methods and results Based on prior published data, we initially calculated the cost of AF for 1995, and then again for 2000 which was calculated from a combination of contemporary and extrapolated data from that time. Taken together the total for these two categories in 2020 would cost the NHS between £949 and £1685 m, depending on the projected increase in annual rate of AF prevalence. The full cost of AF related hospitalizations may be underestimated, due to the other admissions associated with a secondary coding of AF, which in 2020 are forecast to cost between £2269 and £4030 m, depending on the annual population increase of AF prevalence. There will be an increasing number of patients discharged to a nursing home after a hospital admission associated with a principal AF diagnosis, with cost estimates for this in 2000 being £111 m, and predicted to rise to between £346 and £614 m by 2020.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burdett, P., & Lip, G. Y. H. (2022). Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. European heart journal. Quality of care & clinical outcomes. https://doi.org/10.1093/ehjqcco/qcaa093
Vancouver
Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. European heart journal. Quality of care & clinical outcomes. 2022. doi:10.1093/ehjqcco/qcaa093. PMID: 33346822.
BibTeX
@article{burdett2022-33346822,
author = {Burdett, P. and Lip, G. Y. H.},
title = {{Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs}},
journal = {European heart journal. Quality of care \& clinical outcomes},
year = {2022},
doi = {10.1093/ehjqcco/qcaa093},
pmid = {33346822},
url = {https://doi.org/10.1093/ehjqcco/qcaa093}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Atrial fibrillation already accounts for a significant amount of National Health Service (NHS) funding, and over the coming years is highly likely to impose a growing cost on NHS budgets and the wider UK healthcare system.
- Methods and results Based on prior published data, we initially calculated the cost of AF for 1995, and then again for 2000 which was calculated from a combination of contemporary and extrapolated data from that time.
- Taken together the total for these two categories in 2020 would cost the NHS between £949 and £1685 m, depending on the projected increase in annual rate of AF prevalence.
- The full cost of AF related hospitalizations may be underestimated, due to the other admissions associated with a secondary coding of AF, which in 2020 are forecast to cost between £2269 and £4030 m, depending on the annual population increase of AF prevalence.
- There will be an increasing number of patients discharged to a nursing home after a hospital admission associated with a principal AF diagnosis, with cost estimates for this in 2000 being £111 m, and predicted to rise to between £346 and £614 m by 2020.
Study details
- Effect size0.91%; 1.11%; 1.62%
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European heart journal. Quality of care & clinical outcomes) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33346822) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Vascular contributions from nearby years
Also in Vascular contributions
53 studies in the library are filed under Vascular contributions with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Vascular contributions hub.